FDA ap­proves Dupix­ent for hives, re­jects new Eylea dos­ing sched­ule

The FDA made two de­ci­sions on Re­gen­eron’s best-sell­ing drugs Fri­day, hand­ing down one ap­proval and one re­jec­tion.

The ap­proval came for Dupix­ent, the megablock­buster Re­gen­eron …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER